119 related articles for article (PubMed ID: 27010394)
21. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
22. Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer.
Pippen J; Paul D; Vukelja S; Clawson A; Iglesias J
Breast Cancer Res Treat; 2011 Dec; 130(3):825-31. PubMed ID: 21976055
[TBL] [Abstract][Full Text] [Related]
23. Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
Nakatsukasa K; Ouchi Y; Sakaguchi K; Goto M; Konishi E; Taguchi T
Anticancer Res; 2018 Sep; 38(9):5459-5463. PubMed ID: 30194203
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
25. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
26. [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
Arakawa S; Horiguchi A; Tomishige H; Kawabe N; Nagata H; Ishihara S; Ito M; Asano Y; Ito R; Isetani M; Shimizu K; Kamio K; Kawai T; Yasuoka H; Imaeda Y
Gan To Kagaku Ryoho; 2018 Apr; 45(4):649-651. PubMed ID: 29650823
[TBL] [Abstract][Full Text] [Related]
27. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
28. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
[TBL] [Abstract][Full Text] [Related]
29. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Diéras V; Wildiers H; Jassem J; Dirix LY; Guastalla JP; Bono P; Hurvitz SA; Gonçalves A; Romieu G; Limentani SA; Jerusalem G; Lakshmaiah KC; Roché H; Sánchez-Rovira P; Pienkowski T; Seguí Palmer MÁ; Li A; Sun YN; Pickett CA; Slamon DJ
Breast; 2015 Jun; 24(3):182-90. PubMed ID: 25747197
[TBL] [Abstract][Full Text] [Related]
30. Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
Polyzos A; Kalbakis K; Kentepozidis N; Giassas S; Kalykaki A; Vardakis N; Bozionelou V; Saloustros E; Kontopodis E; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2011 Jul; 68(1):217-23. PubMed ID: 20922389
[TBL] [Abstract][Full Text] [Related]
31. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer.
Tiainen L; Tanner M; Lahdenperä O; Vihinen P; Jukkola A; Karihtala P; Paunu N; Huttunen T; Kellokumpu-Lehtinen PL
Anticancer Res; 2016 Dec; 36(12):6431-6438. PubMed ID: 27919965
[TBL] [Abstract][Full Text] [Related]
33. [Liver Atrophy and Failure Associated with Paclitaxel and Bevacizumab Combination Therapy for Metastatic Breast Cancer].
Yamamoto M; Ikeda M; Kubo S; Tsukioki T; Nakamoto S
Gan To Kagaku Ryoho; 2016 Jul; 43(7):869-73. PubMed ID: 27431631
[TBL] [Abstract][Full Text] [Related]
34. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Bisagni G; Musolino A; Panebianco M; De Matteis A; Nuzzo F; Ardizzoni A; Gori S; Gamucci T; Passalacqua R; Gnoni R; Moretti G; Boni C
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1051-7. PubMed ID: 23377310
[TBL] [Abstract][Full Text] [Related]
35. [Breast Cancer with Multiple Liver Metastases Successfully Treated with Capecitabine Monotherapy after Failure of Combination Therapy Comprising Bevacizumab and Paclitaxel].
Ooe A; Suganuma Y
Gan To Kagaku Ryoho; 2016 Mar; 43(3):349-51. PubMed ID: 27067853
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Drooger JC; van Tinteren H; de Groot SM; Ten Tije AJ; de Graaf H; Portielje JE; Jager A; Honkoop A; Linn SC; Kroep JR; Erdkamp FL; Hamberg P; Imholz AL; van Rossum-Schornagel QC; Heijns JB; van Leeuwen-Stok AE; Sleijfer S
Cancer; 2016 Oct; 122(19):2961-70. PubMed ID: 27315546
[TBL] [Abstract][Full Text] [Related]
38. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
[TBL] [Abstract][Full Text] [Related]
39. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
40. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]